Immunocore Holdings plc

Research Immunocore Holdings plc (IMCR) on Bullrun: market cap USD 1.55B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIMCR
• ExchangeNASDAQ
• CountryUnited Kingdom
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.55B
• Financial periodFY2025
• RevenueUSD 400.02M
• Revenue growth29.0%
• Net income-USD 35.51M
• Free cash flow-USD 15.05M
• Gross margin98.7%

Valuation Snapshot

latest market cap is USD 1.55B.

About Immunocore Holdings plc

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma;

Frequently asked questions

What is Immunocore Holdings plc's market cap?

Immunocore Holdings plc's market capitalization is USD 1.55B.

What does Immunocore Holdings plc do?

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally.